References
- Wandell P, Carlsson AC, Sundquist J, Johansson SE, Bottai M, Sundquist K. Effect of cardiovscular drugs on mortality in atrial fibrillation and chronic heart failure. Scand Cardiovasc J. 2014;48:291–8.
- Author not given. Stroke prevention in atrial fibrillation study. Final results. Circulation. 1991;84:527–39.
- , European Heart Rhythm Association; European Association for Cardio-Thoracic SurgeryCamm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–429.
- van der Harst P, Voors AA, van Gilst WH, Böhm M, van Veldhuisen DJ. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res. 2006;71:443–54.
- Andersen LV, Vestergaard P, Deichgraeber P, Lindholt JS, Mortensen LS, Frost L. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. Heart. 2008;94:1607–13.
- Lee M, Saver JL, Hong KS, Wu HC, Ovbiagele B. Risk- benefit profile of warfarin versus aspirin in patients with heart failure and sinus rhythm: a meta-analysis. Circ Heart Fail. 2013;6:287–92.
- Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. 2014 Aug 5. pii: mdu225. [Epub ahead of print].